Previous article

The Chinese NDRC fines two pharmaceutical companies for excessive pricing and refusal to deal (Zhejiang Second Pharma / Tianjin Handewei Pharmaceuticals)

On 31 July 2017, the NDRC publicly announced its decision to sanction Zhejiang Second Pharma (an affiliate of a

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • University of Melbourne
  • Hogan Lovells (Beijing)
  • University of Melbourne
  • China Competition Bulletin (Beijing)

Quotation

Allan Fels, Adrian Emch, Wendy Ng, Xiaoye Wang, The Chinese NDRC fines two pharmaceutical companies for excessive pricing and refusal to deal (Zhejiang Second Pharma / Tianjin Handewei Pharmaceuticals), 31 July 2017, e-Competitions Bulletin July 2017, Art. N° 88631

Visites 61

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues